In humans, further studies should explore the effects of liraglutide on PAH markers such as brain natriuretic peptide and high-sensitive C-reactive protein, to further confirm that liraglutide may be used in the clinical treatment of PAH. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.